Premium
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Author(s) -
Lee Hans C.,
Shah Jatin J.,
Feng Lei,
Morphey Ashley,
Johnson Ralph J.,
Wesson Emily T.,
Wang Michael L.,
Alexanian Raymond,
Thomas Sheeba K.,
Orlowski Robert Z.,
Weber Donna M.
Publication year - 2019
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25633
Subject(s) - lenalidomide , thalidomide , multiple myeloma , medicine , pharmacology , dexamethasone , oncology , bortezomib , cancer research